In a significant move to combat the outbreaks of mpox disease in African nations, the global vaccine alliance Gavi has announced the procurement of 500,000 doses of mpox vaccine. Manufactured by Danish company Bavarian Nordic, these vaccine doses are expected to be made available within this year, although specific dates have not been disclosed.
Gavi revealed that the total costs associated with the acquisition, transportation, delivery, and administration of the doses will amount to $50 million. This financial commitment will be covered by Gavi's First Response Fund, a newly established financial mechanism introduced in June 2024.
